Atorvastatin and simvastatin separately target farnesylation of Rheb and RhoA activity (88), and showed distinct effects in preclinical in vivo studies in which atorvastatin did not reduce tumor growth or improve survival in a Tsc2+/– mouse model with kidney and liver tumors while simvastatin inhibited tumor growth in a model of TSC2-null subcutaneous tumors (14, 89). Here, RHOA is linked to neoplasm.